Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma

International Journal of Gynecological Cancer

Volumn 18, Issue 1, 2008, Pages 85-89

  Mori, T ^a   Hosokawa, K ^a   Kinoshita, Y ^a   Watanabe, A ^a   Honjo, H ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Carboplatin; Cervical cancer; Neoadjuvant chemotherapy; Paclitaxel; Weekly schedule

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 38049046225     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00963.x     Document Type: Article

References (31)

1. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologist. Obstet Gynecol 2002 99 : 855 67.
2. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol 1999 17 : 1339 48.
3. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999 340 : 1137 43.
4. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999 340 : 1144 53.
5. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. N Engl J Med 1999 340 : 1154 61.
6. Peters WA III., Liu PY, Barrett RJ II. et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000 18 : 1606 13.
7. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993 341 : 418 22.
8. Lehman M, Thomas G. Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer? Int J Gynecol Cancer 2001 11 : 87 99.
9. Sardi JE, Boixadera MA, Sardi JJ. A critical overview of concurrent chemoradiotherapy in cervical cancer. Curr Oncol Rep 2004 6 : 463 70.
10. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer 2003 39 : 2470 86.
11. Sardi J, Sananes C, Giaroli A et al. Is subradical surgical treatment for carcinoma of the cervix uteri stage IB logical? Gynecol Oncol 1989 32 : 360 4.
12. Sardi J, Sananes C, Giaroli A, Maya G, di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 1990 38 : 486 93.
13. Dottino PR, Plaxe SC, Beddoe AM, Johnston C, Cohen CJ. Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol 1991 40 : 7 11.
14. Serur E, Mathews RP, Gates J, Levine P, Maiman M, Remy JC. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Gynecol Oncol 1997 65 : 348 56.
15. Benedetti-Panici P, Greggi S, Colombo A et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002 20 : 179 88.
16. Sugiyama T, Nishida T, Kumagai S et al. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical carcinoma. Br J Cancer 1999 81 : 95 8.
17. Umesaki N, Fujii T, Nishimura R et al. Japan Gynecologic Oncology Group. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 2004 95 : 127 32.
18. Zanetta G, Lissoni A, Pellegrino A et al. Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer. Ann Oncol 1998 9 : 977 80.
19. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol 2001 12 : 541 7.
20. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A et al. A phase II study of multimodality treatment for locally advanced cervical cancer; neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol 2003 14 : 1278 84.
21. Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004 92 : 59 63.
22. Papadimitriou CA, Sarris K, Moulopoulos LA et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999 17 : 914 20.
23. Rose PG, Blessing JA, Gershenson DM, Mcgehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999 17 : 2676 80.
24. Ozols RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 2000 27 : 3 7.
25. Muggia FM, Gill I. Role of carboplatin in endometrial and cervical carcinomas. Semin Oncol 1992 19 : 90 3.
26. Markman M, Rose PG, Jones E et al. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 1988 16 : 1849 51.
27. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005 23 : 5983 92.
28. Schmidt-Rhode P, Schulz KD, Sturm G, Hafner H, Prinz H, Kunzig HJ. Squamous cell carcinoma antigen for monitoring cervical cancer. Int J Biol Markers 1988 3 : 87 94.
29. Stebbing JJ, Gaya A. The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer 2001 8 : 23 37.
30. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 2004 11 : 139 47.
31. Candelaria M, Chanona-Vilchis J, Cetina L et al. Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int Semin Sur Oncol 2006 3 : 3.